Astrazeneca Pharma India Ltd vs Kimia Biosciences Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Astrazeneca Pharma India Ltd is ₹ 8213 as of 04 May 09:37 . The P/E Ratio of Astrazeneca Pharma India Ltd changed from 80.7 on March 2021 to 185.9 on March 2025 . This represents a CAGR of 18.16% over 5 yearsThe P/E Ratio of Kimia Biosciences Ltd changed from 35.1 on March 2021 to 20.9 on March 2025 . This represents a CAGR of -9.85% over 5 years The Market Cap of Astrazeneca Pharma India Ltd changed from ₹ 7525 crore on March 2021 to ₹ 21515 crore on March 2025 . This represents a CAGR of 23.38% over 5 yearsThe Market Cap of Kimia Biosciences Ltd changed from ₹ 179.55 crore on March 2021 to ₹ 201.13 crore on March 2025 . This represents a CAGR of 2.30% over 5 years The revenue of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 618.18 crore as compare to the Sep '25 revenue of ₹ 565.26 crore. This represent the growth of 9.36% The revenue of Kimia Biosciences Ltd for the Dec '25 is ₹ 30.2 crore as compare to the Sep '25 revenue of ₹ 33.67 crore. This represent the decline of -10.31% The ebitda of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 51.44 crore as compare to the Sep '25 ebitda of ₹ 76.06 crore. This represent the decline of -32.37% The ebitda of Kimia Biosciences Ltd for the Dec '25 is ₹ 6.65 crore as compare to the Sep '25 ebitda of ₹ 2.19 crore. This represent the growth of 203.65% The net profit of Astrazeneca Pharma India Ltd changed from ₹ -11.79 crore to ₹ 32.59 crore over 7 quarters. This represents a CAGR of NaN% The net profit of Kimia Biosciences Ltd changed from ₹ 1.44 crore to ₹ 5.44 crore over 7 quarters. This represents a CAGR of 113.72% The Dividend Payout of Astrazeneca Pharma India Ltd changed from 5.36 % on March 2021 to 69.12 % on March 2025 . This represents a CAGR of 66.76% over 5 yearsThe Dividend Payout of Kimia Biosciences Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Astrazeneca Pharma India Ltd

AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979.
The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology. AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.

About Kimia Biosciences Ltd

Kimia Bio-sciences Limited (Formerly known Laurel Organics Limited) was incorporated in September, 1993 led by the Promoters, A K Bansal, K S Varma, Atul Sharma, A P Godiyal, D K Gupta and R K Bansal.
The Company has own manufacturing of Bulk Drugs-APIs at its plant located at Gurgaon, Haryana.
The Company is engaged into the business of Pharamaceutical products. The company set up a bulk drug manufacturing unit at Gurgaon, Haryana, at a project cost of Rs 10.41 cr.
It came out with a public issue in Feb.'95 to part-finance the project.
Commercial production commenced in May '95. During the 1998-99, the company has become a sick industrial units. The Hon'ble BIFR vide order dated 27th December, 2005 had deregistered the Company as Sick Industrial Undertaking on the ground that 100% of the capacity was utilized for manufacture of the intermediate products for M/s Ranbaxy Laboratoty Limfted (RLL) and , thereby, turning-out to be an ancillary industrial Undertaking.

FAQs for the comparison of Astrazeneca Pharma India Ltd and Kimia Biosciences Ltd

Which company has a larger market capitalization, Astrazeneca Pharma India Ltd or Kimia Biosciences Ltd?

Market cap of Astrazeneca Pharma India Ltd is 20,543 Cr while Market cap of Kimia Biosciences Ltd is 166 Cr

What are the key factors driving the stock performance of Astrazeneca Pharma India Ltd and Kimia Biosciences Ltd?

The stock performance of Astrazeneca Pharma India Ltd and Kimia Biosciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Astrazeneca Pharma India Ltd and Kimia Biosciences Ltd?

As of May 4, 2026, the Astrazeneca Pharma India Ltd stock price is INR ₹8217.2. On the other hand, Kimia Biosciences Ltd stock price is INR ₹35.21.

How do dividend payouts of Astrazeneca Pharma India Ltd and Kimia Biosciences Ltd compare?

To compare the dividend payouts of Astrazeneca Pharma India Ltd and Kimia Biosciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.